Cue Biopharma
CUE
74 hedge funds and large institutions have $185M invested in Cue Biopharma in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
17% more funds holding
Funds holding: 63 → 74 (+11)
10% more capital invested
Capital invested by funds: $168M → $185M (+$17.5M)
0.11% more ownership
Funds ownership: 1.53% → 1.64% (+0.11%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $443K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$17.8M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$8.65M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$6.7M |
| 4 |
Goldman Sachs
New York
|
+$2.53M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$1.14M |
| 2 |
BlackRock
New York
|
-$942K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$715K |
| 4 |
Morgan Stanley
New York
|
-$595K |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$473K |
CUE Hedge Fund Activity: Q1 2020 in Review
74 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2020, worth a combined $185M — up 10% from $168M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CUE positions and 6 closed out — a net gain of 12 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $17.8M. The largest seller was Sanders Morris Harris, exiting entirely with an estimated $1.14M sold.
- 74 institutional investors held Cue Biopharma (CUE) as of Q1 2020, up from 63 in Q4 2019.
- Funds reported $185M of Cue Biopharma stock for Q1 2020, up 10% quarter-over-quarter.
- 18 funds opened new Cue Biopharma positions in Q1 2020 and 6 closed out, a net change of +12 holders.
- The largest Cue Biopharma buyer in Q1 2020 was Nantahala Capital Management, an estimated $17.8M added.
- The largest Cue Biopharma seller in Q1 2020 was Sanders Morris Harris, an estimated $1.14M sold.
Based on aggregated 13F filings for Q1 2020.